|
Index | - | P/E | - | EPS (ttm) | -0.44 | Insider Own | 4.36% | Shs Outstand | 12.99M | Perf Week | -7.64% |
Market Cap | 22.26M | Forward P/E | - | EPS next Y | -1.06 | Insider Trans | 0.00% | Shs Float | 12.42M | Perf Month | 0.00% |
Income | -2.90M | PEG | - | EPS next Q | -0.24 | Inst Own | 8.34% | Short Float | 0.10% | Perf Quarter | -30.73% |
Sales | - | P/S | - | EPS this Y | 13.00% | Inst Trans | - | Short Ratio | 0.10 | Perf Half Y | -35.12% |
Book/sh | 1.03 | P/B | 1.29 | EPS next Y | - | ROA | -20.90% | Target Price | - | Perf Year | -7.60% |
Cash/sh | - | P/C | - | EPS next 5Y | - | ROE | -39.70% | 52W Range | 1.11 - 8.19 | Perf YTD | -35.12% |
Dividend | - | P/FCF | - | EPS past 5Y | 10.90% | ROI | - | 52W High | -83.75% | Beta | 0.50 |
Dividend % | - | Quick Ratio | 19.40 | Sales past 5Y | - | Gross Margin | - | 52W Low | 19.82% | ATR | 0.19 |
Employees | - | Current Ratio | 19.40 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 45.97 | Volatility | 15.80% 14.17% |
Optionable | No | Debt/Eq | 0.00 | EPS Q/Q | 0.20% | Profit Margin | - | Rel Volume | 0.05 | Prev Close | 1.35 |
Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | - | Payout | - | Avg Volume | 117.24K | Price | 1.33 |
Recom | - | SMA20 | -6.34% | SMA50 | -9.18% | SMA200 | -39.11% | Volume | 5,236 | Change | -1.48% |
![]() |
|
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite